113 results about "Bifidobacterium breve" patented technology

The invention relates to a preparation method of a rice leavening with a scalp care effect and a product and application thereof, the preparation method comprises the following steps: mixing a rice raw material, a plant raw material, water, a magnesium salt, a sodium salt and Tween, sterilizing to obtain a fermentation medium, inoculating a compound microbial agent into the fermentation medium, and fermenting to obtain the rice leavening with the scalp care effect. After the fermentation liquid is finished, sterilizing and filtering to obtain a rice leavening; wherein the compound microbial agent comprises a first microbial strain and a second microbial strain; the strains in the first microbial strain comprise a combination of streptococcus thermophilus, bifidobacterium breve and a plant lactobacillus YK-L002 strain; and the second microbial strain comprises a trichosporon YK-S004 strain. According to the invention, specific strains are subjected to compounding and combined fermentation, and the fermentation product filtrate obtained after fermentation treatment of four bacteria has excellent hair care and nourishing effects, and can effectively condition the scalp micro-ecological environment and nourish the hair quality.

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention belongs to the technical field of microorganisms, and relates to a bifidobacterium breve strain capable of relieving constipation, the strain is bifidobacterium breve Bb-PG-14, the classification name of the strain is Bifidobacterium breve, the preservation number is CGMCC No.31861, the preservation time is September 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, and the preservation number is CGMCC No.31861. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from excrement of healthy babies, has relatively strong acid resistance, alkali resistance, cholate resistance and artificial simulated gastrointestinal fluid tolerance, and has the characteristics of probiotics.

The present invention provides a nutritional composition comprising at least one lactose-N-fucose pentasaccharide, in particular lactose-N-fucose pentasaccharide-I (LNFP-I) or a combination of lactose-N-fucose pentasaccharide-I (LNFP-I), lactose-N-fucose pentasaccharide-II (LNFP-II) and lactose-N-fucose pentasaccharide-III (LNFP-III), for use in improving brain development and / or cognitive development in a subject. There is also provided a nutritional composition comprising at least one lactose-N-fucopentasaccharide, in particular lactose-N-fucopentasaccharide-I (LNFP-I) or a combination of lactose-N-fucopentasaccharide-I (LNFP-I), lactose-N-fucopentasaccharide-II (LNFP-II) and lactose-N-fucopentasaccharide-III (LNFP-III), and Bifidobacterium bifidobacterium.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

The invention discloses a preparation method of acete chinensis buckwheat noodles, and belongs to the technical field of food processing. The present invention provides an acetes chinensis buckwheat noodle preparation method, which comprises: (1) cleaning fresh acetes chinensis to remove impurities, washing with clear water, adding water, and pulping; then adding fructo-oligosaccharide, and sterilizing to obtain an acete chinensis mixture; (2) adjusting the pH value of the acete chinensis mixture to 3.0-5.0, and simultaneously adding acid protease and bifidobacterium breve for enzymolysis-fermentation treatment; and (3) mixing the acete chinensis pulp obtained after the enzymolysis-fermentation treatment with sweet buckwheat flour, vital gluten, konjaku flour and high-gluten wheat flour, kneading dough, performing extrusion forming, and performing vacuum drying to obtain the final acete chinensis buckwheat noodles. The acete chinensis and buckwheat noodles prepared by the method reduce allergens in acete chinensis, produce nutrient substances through probiotic fermentation, and have good taste.

A cognitive function-improving agent containing one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175 as an active ingredient for administration to a subject who has not developed dementia is provided.

The invention discloses a preparation method of zero-lactose yoghurt fermented milk for infants, which specifically comprises the following steps: firstly, performing high-temperature sterilization on raw milk, then cooling, and adding lactase Nola Fit 5500 before fermentation to perform pre-hydrolysis of lactose so as to ensure zero lactose of the product from the source. Then, compound probiotics composed of bifidobacterium animalis subsp. Lactis HN019, lactobacillus mucus fermentation CECT5716, lactobacillus rhamnosus HN001 and bifidobacterium breve M-16V are added, low-temperature slow fermentation is carried out for 15 hours at the temperature of 41 + / -1 DEG C, and no exogenous sugar is added in the whole process. According to the process, nutritional ingredients are reserved to the maximum extent through mild fermentation, formation of natural flavor is promoted, and the obtained product is safe, nutritional and easy to digest and can effectively improve intestinal health of infants and reduce the risk of digestion discomfort.

Provided is a mixed strain with both excellent anti-inflammatory activity and excellent productivity, including Bifidobacterium animalis subsp. lactis LM1017 (Accession No. KCCM12629P), Bifidobacterium n breve LM1092 (Accession No. KCCM13464P), Bifidobacterium longum LM1024 (Accession No. KCCM12919P), and Bifidobacterium bifidum LM1108 (Accession No. KCCM13463P). The strain provided herein has an excellent commercial viability of probiotics.

The invention relates to the technical field of functional foods, in particular to a fermented cereal formula food for controlling sugar and a preparation method thereof, three strains synergistically ferment cereals, and are compounded with a high-activity white hyacinth bean alpha-amylase inhibitor, high-purity mulberry leaf superfine powder and chromium-enriched yeast to jointly construct a multi-way blood sugar regulation and control system; according to the formula, three proteins of soybeans, whey and peas are combined with dietary fibers and prebiotics, the nutritional structure is optimized, satiety is enhanced, traditional herbal essences such as bitter gourds and Chinese yams are supplemented, the dual goals of scientific sugar control and nutrition balance are achieved through precise proportioning, deep biotransformation of cereal nutritional ingredients is achieved through a three-strain staged synergistic fermentation technology, and the nutritional value of the whole grain is improved. According to the present invention, the deep biological conversion of cereal nutritional components is achieved through the protein hydrolysis and glycoside hydrolysis ability of the lactobacillus plantarum, the glutamic acid decarboxylation ability of the bifidobacterium breve, and the vitamin synthesis and chromium enrichment ability of the saccharomyces cerevisiae;

The invention relates to the technical field of biological medicines, and aims to provide a novel application of bifidobacterium breve in preparation of a medicine for preventing and / or treating melanoma, and the purpose of preventing and treating melanoma is achieved by changing the immune microenvironment of melanoma by using microorganisms.

The invention provides UVB damage repair application of a grease composition containing safflower seed oil and fermented artemisia apiacea oil. The fermented artemisia apiacea oil is prepared by the following steps: (a) carrying out supercritical CO2 extraction on artemisia apiacea medicinal materials; (b) fermenting, namely fermenting by adopting bifidus yeast; (c) separating to obtain fermented artemisia apiacea oil; wherein the bifidobacterium is selected from bifidobacterium adolescentis, bifidobacterium animalis subspecies, bifidobacterium animalis subspecies lactis, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum subspecies longum or bifidobacterium longum subspecies infantis. The invention further relates to application of the grease composition containing the safflower seed oil and the fermented artemisia apiacea oil in preparation of a skin external preparation with a UVB damage repairing effect.

The invention discloses bifidobacterium breve CCFM1505 capable of regulating skin ceramide de novo synthesis and improving skin health and a metagen thereof, and belongs to the technical field of microorganisms and medicines. The bifidobacterium breve CCFM1505 obtained through screening shows the effect of remarkably promoting skin ceramide synthesis in the aspects of external use and oral administration. The viable bacteria of the bifidobacterium breve CCFM1505 and the metabiotics thereof, especially the thallus lysate of the bifidobacterium breve, are orally taken, so that the content of ceramide in the skin tissue is remarkably increased, and meanwhile, the effects of increasing of transpedermis water loss, reducing of the water content of cuticle and inflammatory response caused by skin injury and reducing of the ceramide content can be effectively regulated and controlled, and the skin healing effect is improved. Therefore, the skin health is improved. Therefore, the bifidobacterium breve has a huge application prospect in preparation of external or oral medicines for promoting synthesis of skin ceramide and improving skin health, as well as in preparation of foods, health-care products or cosmetics.

The application discloses a streptococcus and application thereof, and belongs to the technical field of microorganisms. The application screens a streptococcus capable of decomposing and utilizing breast milk oligosaccharides, and the streptococcus can grow by taking breast milk oligosaccharides as a carbon source, the utilization rate of 2'-fucosyllactose, 6'-sialyllactose and lacto-N-tetraose reaches more than 99.80%, and the streptococcus is helpful to promoting the growth of short bifidobacterium which cannot utilize 6'-SL.

The application discloses a preparation method and application of a composite strain of a sugar-controlling probiotic, and belongs to the technical field of microorganisms. The method comprises the steps of strain stock solution preparation, anaerobic culture, pH value determination and regulation, and composite strain proportioning. Through a dynamic shunting mechanism with pH value 4.3 as a threshold, the culture solution lower than the value is subjected to re-acidification treatment, and the culture solution higher than the value is subjected to differential dilution and coating operation. Finally, Lactobacillus gasseri, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Bifidobacterium breve, Bifidobacterium lactis and Bifidobacterium longum are mixed at a preset ratio, and a sustained-release agent is added for storage. The method can significantly improve the screening efficiency of target probiotics, the stability of the composite preparation and the blood glucose regulation effect, and can be widely applied to the development of sugar-controlling probiotic products.

The invention provides a probiotic compound for inhibiting anaphylactic reaction. The probiotic compound is prepared from 5 to 15 parts of lactobacillus rhamnosus, 20 to 30 parts of lactobacillus paracasei, 5 to 15 parts of bifidobacterium animalis subsp. Lactis, 1 to 5 parts of bifidobacterium breve, 1 to 5 parts of lactobacillus acidophilus, 1 to 5 parts of plant lactobacillus, 1 to 5 parts of sake lactobacillus brevis, 1 to 5 parts of bifidobacterium longum subsp. Longum and 40 to 55 parts of fructo-oligosaccharide. The probiotic compound is fermented in intestinal tracts to generate metabolite-short-chain fatty acid (consisting of fatty acid with 1-6 carbon atom main chains); the short-chain fatty acid has an anti-inflammatory effect and can enhance an immune protection barrier, such as induction of expansion and de novo differentiation of regulatory T cells; the short-chain fatty acid is a molecule necessary for a B cell differentiation process, and can increase the intake of glucose and promote up-regulation of CXCR < 5 + > and PD-1, so that the growth and development of Tfh cells are realized, and the effect of improving anaphylactic reaction is achieved.

A method of treating, preventing or ameliorating at least one symptom of obsessive compulsive disorder (OCD) in a subject is disclosed. The method comprises a step in which a multistrain probiotic formulation is administered to the subject. The multistrain probiotic formulation includes the bacterial strains Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve and Bifidobacterium infantis and Glutamine in a concentration range of 100-500 mg.

The application discloses a glutamate decarboxylase multi-site combined mutant and application thereof. The application finds key sites by analyzing the enzyme structure and amino acid sequence of glutamate decarboxylase from Bifidobacterium breve and human GAD65, finally the key amino acid residue sites in the catalytic region and the vicinity of the active center are reformed (C168M, V167F, Y165S, F304Y, Y308F), so that the catalytic activity and specificity of the glutamate decarboxylase are regulated, the reaction type is changed from decarboxylation to incomplete oxidation, and the catalysis of glutamic acid forms the oxidation byproduct succinamic acid. In the process of GAD producing succinamic acid, the side reaction is enhanced, and the main reaction is weakened, so that the produced GABA is further oxidized into succinamic acid. The biological catalysis method can effectively improve the screening probability of the mutant amino acid sites, improve the experimental efficiency and feasibility, and screen the mutant enzyme with enzyme activity obviously superior to the parent enzyme.

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.

In some embodiments, a composition comprising an effective amount of Bifidobacterium breve, Bifidobacterium bifidum, and Lactobacillus salivarius is provided. In some embodiments, the use of the composition in the prevention or treatment of atopic eczema in a subject is provided. In some embodiments, there is provided a method of preventing or treating atopic eczema in a subject, the method comprising the step of administering to the subject an effective amount of the composition. In some embodiments, there is provided a kit comprising: a composition of any one of the examples herein; and at least one container selected from the group consisting of capsules, pouches, packets, sachets, bottles, and blister packages. Other exemplary embodiments are described herein. In certain embodiments, the compositions are safe to use and effective to prevent or treat atopic eczema in a subject, especially an adult subject.

This invention provides the application of *Bifidobacterium breve* in the preparation of products for treating gastric ulcers and gastric inflammation caused by *Helicobacter pylori*, belonging to the field of microbial technology. The *Bifidobacterium breve* NKU BB1-2 of this invention, with accession number GDMCC NO: 65956, can antagonize *Helicobacter pylori* colonization and alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori*. In vitro, *Bifidobacterium breve* NKU BB1-2 exhibits good antagonistic ability against *Helicobacter pylori*, significantly inhibiting its colonization and growth. Animal experiments show that *Bifidobacterium breve* NKU BB1-2 can alleviate the aggravation of gastric ulcers caused by *Helicobacter pylori* infection in vivo, manifested as reduced gastric mucosal damage, reduced gastric inflammation, and increased gastric pH. Furthermore, *Bifidobacterium breve* NKU BB1-2 can significantly enhance gastric microbial diversity, regulate and improve the gastric microbial structure, and assist in antagonizing and eradicating *Helicobacter pylori* infection.

The application provides a composition of 2'-fucosyllactose and probiotics and application thereof, and belongs to the technical field of probiotics.The effective component of the composition is composed of 2'-fucosyllactose, Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium longum subsp. infantis M-63.The compounding of the probiotics and 2'-fucosyllactose has a good relieving effect on rhinitis and rhinitis sensitivity, and has a good market application prospect.

The preparation method comprises the following steps: mixing and crushing the following components in parts by weight: 10-15 parts of astragalus membranaceus, 2-3 parts of paris polyphylla, 2-6 parts of liquorice, 3-5 parts of pseudo-ginseng, 1-2 parts of pericarpium citri reticulatae, 20-30 parts of American ginseng, 5-10 parts of angelica sinensis and 4-5 parts of fructus gardeniae, and then performing purification treatment to obtain a composition I; 0.02 to 0.05 part of bifidobacterium lactis, 0.02 to 0.05 part of bifidobacterium breve, 0.02 to 0.08 part of lactobacillus rhamnosus and 0.01 to 0.02 part of lactobacillus acidophilus are used for preparing microcapsule powder, and the microcapsule powder is used as a composition II; and mixing the composition I and the composition II according to a mass ratio of (8: 1)-(10: 1) to obtain the probiotic composition for enhancing immunity. The defects in the prior art can be overcome, and the immunity is effectively improved.

The invention discloses an anaerobic bacterium co-culture device and application thereof.The anaerobic bacterium co-culture device comprises a first screw injector 1 and a second screw injector 8, the first screw injector 1 is sequentially connected with a first Luer external thread adapter 2, a first hose 3, a filter membrane clamp 4, a second hose 5, a second Luer external thread adapter 6 and the second screw injector 8, and the first Luer external thread adapter 2, the first hose 3, the filter membrane clamp 4, the second hose 5, the second Luer external thread adapter 6 and the second screw injector 8 are sequentially connected; and a filter membrane 7 is arranged in the filter membrane clamp 4. The anaerobic bacteria co-culture device is simple in structure, low in cost and convenient to use, can easily simulate an anaerobic environment and co-culture anaerobic bacteria without anaerobic culture equipment, can well culture two different species of bacteria in the same liquid environment without cross contamination, is suitable for co-culture of various common anaerobic bacteria, and has a wide application prospect. Such as salmonella typhimurium, bifidobacterium breve, fecal bacillus przewalskii, ackermania or prevotella. The method has great benefits for the initial research of related research projects of bacterial interaction.